Univadis® is a comprehensive online medical-information resource from Aptus Health—a subsidiary of Healthcare Services and Solutions (HSS)—for health care professionals worldwide.
This web- and mobile-optimized resource provides high-quality, relevant and trusted medical information essential for health care practice. The site features breaking medical news, accredited education courses and tools tailored by medical specialty and clinician need. Additionally, a point-of-care mobile application (Consult) is available in key markets. Over 3.5 million health care professionals are registered members of Univadis, which is available across 63 specialties, 20 languages and 90 geographic markets.
The medical and scientific content comes from independent third parties, such as scientific leaders, educational institutions and medical societies, as well as through partnerships with a range of world-leading medical publishers. Sponsor organizations provide educational funding to expand and augment the site’s core content in adherence with the strict editorial principles of independence, relevance and quality.
Univadis is available across 63 specialties, in 20 languages and in 90 geographic markets
With no subscription or registration fees, Univadis provides access to:
- The latest medical news and clinical developments in 60+ specialist areas
- Selected full-text articles from The Lancet and JAMA
- Weekly research summaries from major peer-reviewed publications
- Conference coverage from medical congresses
- Full online access to trusted medical references
- A library of thousands of medical images to enrich presentations and research
- A wide range of resources to enhance interactions with patients at the point of care, including interactive 3-D anatomy tools and patient handouts
Univadis creates unique opportunities for long-term and meaningful partnerships with scientific and health care organizations in addition to the world-class publishers that our company already works with. Univadis aims to be a valuable partner to build lasting relationships with our 2.9 million individual health care users globally.
Antimicrobial Stewardship (AMS) is a rational, systematic approach to the use of antimicrobials in order to optimize patient outcomes and population health, and minimize unintended consequences, such as selection of pathogenic organisms (e.g., Clostridium difficile), toxicity and resistance. Our AMS vision is to be known as a leader within the industry and a sought-after partner within the broader health care community in advancing patient-centered AMS through education, implementation, research and advocacy initiatives with an emphasis on patient outcomes and value of care. We made significant progress toward this goal in 2015.
Education is foundational to AMS, and our company has helped support a variety of educational offerings for health care providers through international, national, regional and state organizations, including those with an infectious diseases-based membership as well as other subspecialty and generalist organizations (e.g., Society for Hospital Medicine). Outside the United States, we provide preceptorships for health care providers to learn firsthand from other providers practicing AMS in Colombia, Mexico and Brazil.
Implementation is required for AMS action and impact. Our company has an ongoing collaboration with an AMS Center of Excellence in Cali, Colombia that has trained over 200 physicians across Latin America and implemented over 70 local hospital protocols. We also participated in the expert panel to develop the National Quality Forum “Antibiotic Stewardship in Acute Care: A Practical Playbook,” which provides practical guidance on options for hospitals and acute care facilities to implement these actions, using their existing resource availability.
Research is needed to build and disseminate evidence regarding AMS best practices and impact on patients and population health. 2015 marked the end of year one in a two-year collaborative project with the CDC/CDC Foundation to develop standardized metrics and an outcomes assessment tool for AMS programs related to patient safety and quality of care. Our company also supports an investigator-initiated research grant program specific to AMS and has funded 12 studies, between 2013 and 2015.
Advocacy for continued antimicrobial innovation, appropriate antimicrobial stewardship and sustainable access is vital to the fight against antimicrobial resistance. We are active in a number of policy and legislative discussions and initiatives, and have several representatives on the European Innovative Medicines Initiative (IMI) Driving Reinvestment in Research and Development for Antibiotics and Advocating their Responsible Use (DRIVE-AB) work packages.
DRIVE-AB is tasked with defining responsible use of antibiotics, identifying the antibiotic-related population health priorities, calculating the societal value of having new antibiotics available for these priorities and developing economic models to promote the desired antibiotic innovation and sustainable use of the resulting, novel antibiotics.